1910 Genetics

Edit info

Founded: 2018

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: Neurological conditions

Drug types: NEU, INF, IMM, ONC, RAR, GEN

Lead product: Undisclosed

Funding: $22M A Mar 2021; $4.1M Seed

Investors: FoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital, M12

1910genetics.com

linkedin.com

job board

Business:

Computational chemistry platform to develop small molecule therapeutics

Drug notes:

Undisclosed programs RD infectious diseases, immunology conditions, oncology, rare & genetic diseases

About:

1910 Genetics is integrating AI, computation and biological automation to accelerate drug discovery. The current pharmaceutical R&D model is unsustainable, taking 12 to 15 years to bring new drugs to market, costing billions of dollars and having a success rate lower than 10%. 1910 Genetics is using their proprietary machine learning platforms to circumvent these problems by shortening the timeline and reducing operational costs of drug development. Their platforms, ELVIS and ROSALYND, are being employed for novel hit discovery, hit-to-lead and lead optimization for both small molecule and protein therapeutics. 1910 Genetics’ pipeline is disease agnostic, advancing drug discovery for all major diseases.